Skip to main content
SpringerLink
Log in

Idiopathische Lungenfibrose

Wirksamkeit von Nintedanib bei verschiedenen IPF-Subgruppen vergleichbar

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Richeldi L, du Bois RM, Raghu G et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071–2082.

    Article  Google Scholar 

  2. Cottin V, Taniguchi H, Richeldi L et al. Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS trials. Presented at the International Colloquium on Lung and Airway Fibrosis (ICLAF). September 20-24, 2014, Mont Tremblant, Quebec, Canada.

    Google Scholar 

  3. Kolb M, Richeldi L, Kimura T et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS trials [abstract]. Am J Respir Crit Care Med 2015;191:A1021.

    Google Scholar 

  4. Raghu G, Wells A, Nicholson AG et al. Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF [abstract]. Am J Respir Crit Care Med 2015;191:A1022.

    Article  Google Scholar 

Originalie

  • Costabel U, Inoue Y, Richeldi L et al. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–85.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V, Pneumologie Herz-Thorax-Zentrum Fulda, Klinikum Fulda gAG, Pacelliallee 4, 36043, Fulda, Deutschland

    Philipp Markart (Direktor)

  2. Stellvertretender Leiter Schwerpunkt: „Fibrosierende Lungenerkrankungen“, Universitätsklinikum Giessen Marburg GmbH, Klinikstrasse 36, 35392, Giessen, Deutschland

    Philipp Markart (Direktor) &  Andreas Günther (Chefarzt)

  3. AGAPLESION Pneumologische Klinik Waldhof-Elgershausen, 35753, Greifenstein, Deutschland

    Andreas Günther (Chefarzt)

Authors
  1. Philipp Markart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Markart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markart, P., Günther, A. Wirksamkeit von Nintedanib bei verschiedenen IPF-Subgruppen vergleichbar. Pneumo News 8, 20–22 (2016). https://doi.org/10.1007/s15033-016-0436-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-016-0436-4

Search

Navigation